Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 02, 2024

SELL
N/A
-1,153,663 Reduced 20.31%
4,527,122 $15 Million
Q3 2021

Nov 14, 2022

BUY
$20.88 - $56.08 $119 Million - $319 Million
5,680,785 New
5,680,785 $240 Million

Others Institutions Holding ADGI

About Adagio Therapeutics, Inc.


  • Ticker ADGI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 108,831,000
  • Market Cap $505M
  • Description
  • Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...
More about ADGI
Track This Portfolio

Track Alphabet Inc. Portfolio

Follow Alphabet Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alphabet Inc., based on Form 13F filings with the SEC.

News

Stay updated on Alphabet Inc. with notifications on news.